Visual Impairment and Risk of Dementia in 2 Population-Based Prospective Cohorts: UK Biobank and EPIC-Norfolk.


Journal

The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837

Informations de publication

Date de publication:
01 04 2022
Historique:
received: 20 07 2021
pubmed: 1 11 2021
medline: 6 4 2022
entrez: 31 10 2021
Statut: ppublish

Résumé

Visual impairment has emerged as a potential modifiable risk factor for dementia. However, there is a lack of large studies with objective measures of vision and with more than 10 years of follow-up. We investigated whether visual impairment is associated with an increased risk of incident dementia in UK Biobank and European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk). In both cohorts, visual acuity was measured using a "logarithm of the minimum angle of resolution" (LogMAR) chart and categorized as no (≤0.30 LogMAR), mild (>0.3 to ≤0.50 LogMAR), and moderate to severe (>0.50 LogMAR) impairment. Dementia was ascertained through linkage to electronic medical records. After restricting to those aged ≥60 years, without prevalent dementia and with eye measures available, the analytic samples consisted of 62 206 UK Biobank and 7 337 EPIC-Norfolk participants, respectively. In UK Biobank and EPIC-Norfolk, respectively, 1 113 and 517 participants developed dementia over 11 and 15 years of follow-up. Using multivariable Cox proportional-hazards models, the hazard ratios for mild and moderate to severe visual impairment were 1.26 (95% confidence interval [CI]: 0.92-1.72) and 2.16 (95% CI: 1.37-3.40), in UK Biobank, and 1.05 (95% CI: 0.72-1.53) and 1.93 (95% CI: 1.05-3.56) in EPIC-Norfolk, compared to no visual impairment. When excluding participants censored within 5 years of follow-up or with prevalent poor or fair self-reported health, the direction of the associations remained similar for moderate impairment but was not statistically significant. Our findings suggest visual impairment might be a promising target for dementia prevention; however, the possibility of reverse causation cannot be excluded.

Identifiants

pubmed: 34718565
pii: 6412742
doi: 10.1093/gerona/glab325
pmc: PMC8974347
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

697-704

Subventions

Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C864/A14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12015/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : UKRI Future Leaders Fellowship
Organisme : Medical Research Council
ID : MR/T040912/1
Pays : United Kingdom
Organisme : Nicolaus and Margrit Langbehn Foundation
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America.

Références

BMJ. 2020 Feb 12;368:m131
pubmed: 32051121
Br J Cancer. 1999 Jul;80 Suppl 1:95-103
pubmed: 10466767
Alzheimers Dement. 2018 Aug;14(8):1038-1051
pubmed: 29621480
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2162-2168
pubmed: 32043518
BMJ. 2017 Jun 22;357:j2709
pubmed: 28642251
J Am Med Dir Assoc. 2017 May 1;18(5):388-395
pubmed: 28043804
BMJ Open. 2019 Feb 21;9(2):e025077
pubmed: 30796124
Int J Epidemiol. 2014 Aug;43(4):1063-72
pubmed: 23771720
Curr Neuropharmacol. 2018;16(7):971-977
pubmed: 29210654
Psychol Aging. 1994 Sep;9(3):339-55
pubmed: 7999320
Lancet Glob Health. 2021 Feb;9(2):e144-e160
pubmed: 33275949
Brain. 2019 Mar 1;142(3):744-759
pubmed: 30789229
BMJ Open. 2013 Mar 19;3(3):
pubmed: 23516272
J Am Geriatr Soc. 2004 Dec;52(12):1996-2002
pubmed: 15571533
Nat Rev Neurol. 2019 Jan;15(1):11-24
pubmed: 30532084
Health Qual Life Outcomes. 2019 Feb 1;17(1):24
pubmed: 30709406
Br J Ophthalmol. 2021 Sep 13;:
pubmed: 34518160
Qual Life Res. 2018 Aug;27(8):1957-1971
pubmed: 29404924
Alzheimers Dement. 2015 Jan;11(1):70-98
pubmed: 25022540
J Gerontol A Biol Sci Med Sci. 2019 May 16;74(6):890-896
pubmed: 30452551
Eur J Epidemiol. 2019 Jun;34(6):557-565
pubmed: 30806901
Eur J Epidemiol. 2019 Feb;34(2):141-152
pubmed: 30610413
Lancet Glob Health. 2021 Feb;9(2):e130-e143
pubmed: 33275950
Eye (Lond). 2018 Aug;32(8):1296-1303
pubmed: 29610523
Neurosci Biobehav Rev. 2016 Oct;69:166-73
pubmed: 27484869
Emerg Themes Epidemiol. 2016 Oct 28;13:11
pubmed: 27800007
Alzheimers Dement. 2018 Feb;14(2):178-186
pubmed: 28943197
J Alzheimers Dis. 2021;83(3):1073-1087
pubmed: 34397414
JAMA Ophthalmol. 2020 Jun 1;138(6):624-633
pubmed: 32297918
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
Lancet. 2014 Mar 1;383(9919):828-40
pubmed: 23927914
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Am J Epidemiol. 2010 Mar 15;171(6):728-35
pubmed: 20150357
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Ophthalmology. 2021 Aug;128(8):1135-1149
pubmed: 33422559
Psychol Aging. 1997 Mar;12(1):12-21
pubmed: 9100264
Ageing Res Rev. 2015 Sep;23(Pt B):154-66
pubmed: 26123097
Sci Rep. 2020 Jun 4;10(1):9109
pubmed: 32499618
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Int J Epidemiol. 2018 Feb 1;47(1):226-235
pubmed: 29040562
Sci Rep. 2019 Dec 23;9(1):19660
pubmed: 31873079
J Am Geriatr Soc. 2017 Sep;65(9):2074-2081
pubmed: 28734053
Alzheimers Dement (Amst). 2020 Jul 07;12(1):e12054
pubmed: 32671180
Sci Rep. 2018 Feb 1;8(1):2083
pubmed: 29391510
Psychogeriatrics. 2020 May;20(3):262-270
pubmed: 31799771
Lancet Glob Health. 2017 Sep;5(9):e888-e897
pubmed: 28779882
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248

Auteurs

Thomas J Littlejohns (TJ)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Shabina Hayat (S)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Robert Luben (R)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Carol Brayne (C)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Megan Conroy (M)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Paul J Foster (PJ)

NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK.

Anthony P Khawaja (AP)

NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK.
MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.

Elżbieta Kuźma (E)

Albertinen-Haus Centre for Geriatrics and Gerontology, University of Hamburg, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH